Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
|Videos|August 16, 2020
Looking to the future of retina innovations
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.
Advertisement
Advertisement
Related to this article
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: BRUNELLO 1-year results for remigromig in DME
2
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
3
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5